Cyclooxygenase-2 blockade inhibits accumulation and function of myeloid-derived suppressor cells and restores T cell response after traumatic stress

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 34, Issue 2, 2014, Pages 234-240

  Li, Ren Jie ^a   Liu, Lin ^b   Gao, Wei ^a   Song, Xian Zhou ^a   Bai, Xiang Jun ^a   Li, Zhan Fei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

cyclooxygenase 2; myeloid derived suppressor cells; T cell dysfunction; trauma

Indexed keywords

ARG1 PROTEIN, MOUSE; ARGINASE; CD11B ANTIGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; SULFONAMIDE;

ANIMAL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; MYELOID PROGENITOR CELL; PATHOLOGY; POSTTRAUMATIC STRESS DISORDER;

ANIMALS; ANTIGENS, CD11B; APOPTOSIS; ARGINASE; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; MICE; MYELOID PROGENITOR CELLS; NITROBENZENES; STRESS DISORDERS, TRAUMATIC; SULFONAMIDES;

EID: 84898870634     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-014-1264-6     Document Type: Article

References (37)

1. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003,348(16):1546-1554
2. Webster NR, Galley HF. Immunomodulation in the critically ill. Br J Anaesth, 2009,103(1):70-81
3. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis, 2013,13(3):260-268
4. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma, 1995,38(2):185-193
5. Gabrilovich DI, Bronte V, Chen SH, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res, 2007,67(1):425
6. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol, 2009,9(3):162-174
7. Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res, 2007,13(2 pt 2):721s-726s
8. Srivastava MK, Sinha P, Clements VK, et al. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res, 2010,70(1):68-77
9. Sinha P, Clements VK, Fulton AM, et al. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res, 2007,67(9):4507-4513
10. Li W, Wu K, Zhao E, et al. HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection. Biochem Biophys Res Commun, 2013,436(2):156-161
11. Chandra D, Jahangir A, Quispe-Tintaya W, et al. Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice. Br J Cancer, 2013,108(11):2281-2290
12. Fujii W, Ashihara E, Hirai H, et al. Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis. J Immunol, 2013,191(3):1073-1081
13. Ryan SO, Johnson JL, Cobb BA. Neutrophils confer T cell resistance to myeloid-derived suppressor cell-mediated suppression to promote chronic inflammation. J Immunol, 2013,190(10):5037-5047
14. Delano MJ, Scumpia PO, Weinstein JS, et al. MyD88-dependent expansion of an immature GR-1+ CD11b+ population induces T cell suppression and Th2 polarization in sepsis. J Exp Med, 2007,204(6):1463-1474
15. Munera V, Popovic PJ, Bryk J, et al. Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann Surg, 2010,251(1):120-126
16. Sander LE, Sackett SD, Dierssen U, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med, 2010,207(7):1453-1464
17. Ren D, Bi Q, Li L, et al. Myeloid-derived suppressor cells accumulate in the liver site after sepsis to induce immunosuppression. Cell Immunol, 2012,279(1):12-20
18. Makarenkova VP, Bansal V, Matta BM, et al. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol, 2006,176(4):2085-2094
19. Bryk JA, Popovic PJ, Zenati MS, et al. Nature of myeloid cells expressing arginase 1 in peripheral blood after trauma. J Trauma, 2010,68(4):843-852
20. Zhang K, Bai X, Li R, et al. Endogenous glucocorticoids promote the expansion of myeloid-derived suppressor cells in a murine model of trauma. Int J Mol Med, 2012,30(2):277-282
21. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer, 2010,10(3):181-193
22. Rodriguez PC, Hernandez CP, Quiceno D, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med, 2005, 202(7):931-939
23. Mao Y, Poschke I, Wennerberg E, et al. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res, 2013,73(13):3877-3887
24. Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res, 2011, 71(7):2664-2674
25. Liong EC, Xiao J, Lau TY, et al. Cyclooxygenase inhibitors protect D-galactosamine/lipopolysaccharide induced acute hepatic injury in experimental mice model. Food Chem Toxicol, 2012,50(3-4):861-866
26. Li B, Li YM, Li X, et al. COX-2 inhibition improves immune system homeostasis and decreases liver damage in septic rats. J Surg Res, 2009,157(1):43-47
27. Bruegel M, Ludwig U, Kleinhempel A, et al. Sepsis-associated changes of the arachidonic acid metabolism and their diagnostic potential in septic patients. Crit Care Med, 2012,40(5):1478-1486
28. Sadikot RT, Zeng H, Azim AC, et al. Bacterial clearance of Pseudomonas aeruginosa is enhanced by the inhibition of COX-2. Eur J Immunol, 2007,37(4):1001-1009
29. Goldmann O, Hertzén E, Hecht A, et al. Inducible cyclooxygenase released prostaglandin E2 modulates the severity of infection caused by Streptococcus pyogenes. J Immunol, 2010,185(4):2372-2381
30. Nascimento DC, Alves-Filho JC, Sonego F, et al. Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit Care Med, 2010,38(8):1718-1725
31. Hotchkiss RS. Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med, 2003,348(2):138-150
32. Ma J, Zhao X, Su Q, et al. Effect of early intensive insulin therapy on immune function of aged patients with severe trauma. J Huazhong Univ Sci Technolog Med Sci, 2012,32(3):400-404
33. Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood, 2011,118(20):5498-5505
34. Derive M, Bouazza Y, Alauzet C, et al. Myeloid-derived suppressor cells control microbial sepsis. Intensive Care Med, 2012,38(6):1040-1049
35. Cuenca AG, Delano MJ, Kelly-Scumpia KM, et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med, 2011,17(3-4):281-292
36. Brudecki L, Ferguson DA, McCall CE, et al. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect Immun, 2012,80(6):2026-2034
37. Fredenburgh LE, Velandia MM, Ma J, et al. Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis. J Immunol, 2011,187(10):5255-5267